The global small molecule targeted cancer therapy market size is projected to register a high CAGR during the forecast period, 2021–2028. The growth of the market is attributed to its huge adoption rate and minimum adverse effects of the therapy.
The small molecule targeted cancer therapy is a rapidly growing and widely adopted treatment process for targeted cancer patients. In general, patients tend to use several alternative drugs available in the market to treat the disease. However, rising patent expiry of the drugs such as Glivec of Novartis, is an immense opportunity for manufacturers to develop new targeted drugs, which act to prevent cancerous cell growth. Therapies such as conventional medications and chemotherapy are likely to destroy the cells and stop the cell growth rapidly. The small molecule targeted therapy destroy cancer cells with better efficiency and less side effects. There are various types of cancers such as prostate cancer, multiple myeloma, lymphoma, melanoma and breast cancer which are treated by this targeted therapy.
To increase the compliance and self-care ability to the patients who went through small molecule therapy, the International Society of Nurse in Cancer Care initiated Led Small Molecule Chemotherapy Patient Education Program, which is funded by Glaxo Smith Kline. Small molecules target the intra-cellular protein and spike the aperture of a tumor. Identification and purity of small molecule target cancer cells is certified due to purification, chemical synthesis, and molecular characterization techniques to make them effortless to reproduce. Antibodies are regulated intravenously, while small molecules can be orally regulated. Small molecules therapy if proven successful is expected to be another treatment for the cancer immunotherapy.
The report on the global small molecule targeted cancer therapy market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.
Attributes |
Details |
Report Title |
Small Molecule Targeted Cancer Therapy Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast |
Base Year |
2020 |
Historic Data |
2018–2019 |
Forecast Period |
2021–2028 |
Segmentation |
Applications (Small Molecules [Small Molecule Cyclin-dependent Kinase Inhibitor, Small Molecule Tyrosine Kinase Inhibitor, and Small Molecule Proteasome Inhibitor], Monoclonal Antibodies [Fully Human Antibody, Chimeric Monoclonal Antibody, Humanized Monoclonal Antibody, and Humanized Monoclonal Antibody], and Small Molecule Drug Conjugates) |
Regional Scope |
Asia Pacific, North America, Latin America, Europe, and Middle East & Africa |
Report Coverage |
Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast |
Key Players Covered in the Report |
Abbott Laboratories; Boehringer Ingelheim GmbH; Bayer HealthCare AG; Cytokinetics Inc.; Hospira Inc.; OncoGenex Pharmaceuticals Inc.; and GlaxoSmithKline PLC |
Based on applications, the global small molecule targeted cancer therapy market is segregated into small molecules, monoclonal antibodies, and small molecule drug conjugates. The small molecules is further divided into small molecule cyclin-dependent kinase inhibitor, small molecule tyrosine kinase inhibitor, and small molecule proteasome inhibitor. The monoclonal antibodies is sub-classified as fully human antibody, chimeric monoclonal antibody, humanized monoclonal antibody, and humanized monoclonal antibody. The monoclonal antibodies segment is expected to grow at a rapid pace during the forecast period due to its huge adoption rates for the disease treatment. On the other hand, the small molecules segment is estimated to expand at a substantial growth rate during the forecast period owing to high precision and few side effects.
In terms of regions, the market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. The market of North America accounted for a key share of the market in 2020 and is projected to exhibit a high CAGR during the forecast period owing to increasing incidences of cancer in the region. The market of Asia Pacific, however, is estimated to grow at a rapid pace during the forecast period due to growing infrastructure and various initiatives for awareness in people and for R&D activities in the region.
The global small molecule targeted cancer therapy market has been segmented on the basis of
Key players competing in the global small molecule targeted cancer therapy market are Abbott Laboratories; Boehringer Ingelheim GmbH; Bayer HealthCare AG; Cytokinetics Inc.; Hospira Inc.; OncoGenex Pharmaceuticals Inc.; and GlaxoSmithKline PLC. The main market players are continuously engaged in various development activities such as mergers and acquisitions, research and developments, investments for innovative products and collaborations to enhance their market position globally. BeiGene got its cancer drugs in clinic tests, listing poly ADP ribose polymerase inhibitor and a la ibrutinib, BRAF inhibitor.
The global small molecule targeted cancer therapy market has been segmented on the basis of
Key players competing in the global small molecule targeted cancer therapy market are Abbott Laboratories; Boehringer Ingelheim GmbH; Bayer HealthCare AG; Cytokinetics Inc.; Hospira Inc.; OncoGenex Pharmaceuticals Inc.; and GlaxoSmithKline PLC. The main market players are continuously engaged in various development activities such as mergers and acquisitions, research and developments, investments for innovative products and collaborations to enhance their market position globally. BeiGene got its cancer drugs in clinic tests, listing poly ADP ribose polymerase inhibitor and a la ibrutinib, BRAF inhibitor.
Some other reports from this category!